摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-fluorophenyl)-1,5-dimethyl-1,2-dihydro-3H-pyrazol-3-one | 948853-47-2

中文名称
——
中文别名
——
英文名称
2-(2-fluorophenyl)-1,5-dimethyl-1,2-dihydro-3H-pyrazol-3-one
英文别名
2-(2-fluorophenyl)-1,5-dimethyl-1H-pyrazol-3(2H)-one;2-(2-fluoro-phenyl)-1,5-dimethyl-1,2-dihydro-pyrazol-3-one;2-(2-fluorophenyl)-1,5-dimethylpyrazol-3-one
2-(2-fluorophenyl)-1,5-dimethyl-1,2-dihydro-3H-pyrazol-3-one化学式
CAS
948853-47-2
化学式
C11H11FN2O
mdl
——
分子量
206.22
InChiKey
DQPFJFCHXANILT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    23.6
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • New pyrazolones as 11b-HSD1 inhibitors for diabetes
    申请人:Amrein Kurt
    公开号:US20070049574A1
    公开(公告)日:2007-03-01
    Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 to R 4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    公式化合物以及医药可接受的它们的盐和酯,其中R1至R4的意义如权利要求1中所给出,可以用作药物组合物。
  • Late-Stage Diversification of Non-Steroidal Anti-Inflammatory Drugs by Transition Metal-Catalyzed C-H Alkenylations, Thiolations and Selenylations
    作者:Wenbo Ma、Hongbo Dong、Daoxin Wang、Lutz Ackermann
    DOI:10.1002/adsc.201600937
    日期:2017.3.20
    Ruthenium‐ and silver‐catalyzed selective C–H alkenylations, thiolations and selenylations of phenazone (antipyrine) – a non‐steroidal anti‐inflammatory drug – have been developed. This method features ample substrate scope, affording typically the mono‐ortho alkenylated, thiolated and selenylated products in good yields with complete site selectivity control. This strategy offers an efficient protocol
    已开发出非甾体类抗炎药非那酮(安替比林)的催化的选择性C–H链烯基化,醇化和化作用。该方法具有足够的底物范围,通常可提供高收率的单邻链烯基化,醇化和代化产物,并能完全控制位点选择性。该策略为修饰安替比林生物提供了有效的方法。
  • Carboxamide derivatives
    申请人:Edwards Anne-Marie
    公开号:US09403833B2
    公开(公告)日:2016-08-02
    The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or co-crystal thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了公式(I)的化合物或其药学上可接受的盐或共晶体;本发明还提供了制造该化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合物和制药组合物。
  • Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists
    作者:Cécile Pégurier、Philippe Collart、Pierre Danhaive、Sabine Defays、Michel Gillard、Frédéric Gilson、Thierry Kogej、Patrick Pasau、Nathalie Van Houtvin、Marc Van Thuyne、BerendJan van Keulen
    DOI:10.1016/j.bmcl.2007.05.035
    日期:2007.8
    The discovery and optimization of a novel class of potent CCR3 antagonists is described. Details of synthesis and SAR are given together with some ADME properties of selected compounds. An optimal balance between activities, physicochemical properties, and in vitro metabolic stability was reached by the proper choice of substituents. (c) 2007 Elsevier Ltd. All rights reserved.
  • METHODS OF IDENTIFYING AND TREATING INDIVIDUALS EXHIBITING MUTANT SRC KINASE POLYPEPTIDES
    申请人:Bristol-Myers Squibb Company
    公开号:EP1904654A2
    公开(公告)日:2008-04-02
查看更多